Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the ...

Q3 2025 Earnings Call Transcript November 4, 2025 Crexendo, Inc. beats earnings expectations. Reported EPS is $0.1, ...

Follow here for live coverage of Election Day 2025, including news, check-ins and results, from the New Jersey governor's ...